News

JFK Airport Chooses LOGIPIX for Airside Virtual Ramp Control System

JFK Millennium Partners, the consortium leading a $4.2 billion redevelopment at JFK International Airport, has selected LOGIPIX US Corporation to implement an advanced Virtual Ramp Control System at the new JFK Terminal 6. This pioneering technology promises to revolutionize airport operations by enhancing security, efficiency, and safety on the ground.

LOGIPIX, a global leader in high-resolution intelligent computer vision solutions, was chosen after a rigorous selection process for its advanced capabilities and track record of successful implementations in high-volume commercial airside environments, such as LaGuardia Airport.

The Virtual Ramp Control System will leverage LOGIPIX’ innovative multi-sensor panoramic video technology and Airside Augmented Reality Solution (LAARS) software to provide monitoring and analysis of ground activities with live object classification and tracking, supporting the Terminal 6 gate operations center. Integrating high-resolution cameras, intelligent AI analytics, and advanced control features, the system will enhance the efficiency of aircraft management with real time decision-making support and improved situational awareness.

“We are thrilled to work with JFK Millennium Partners to deploy our Virtual Ramp Control System,” said Mike Broggie, President of LOGIPIX US Corporation. “This collaboration underscores our commitment to provide cutting-edge solutions that address the evolving needs of modern airports, and we are confident that our technology will contribute to JFK’s innovative transformation into a world-class facility.”

Implementation of the Virtual Ramp Control System will occur in two phases during construction of Terminal 6.

Recent News

06/11/2026

Adial Pharmaceuticals Announces Acquisition of Azora Therapeutics and up to $64 Million Financing

Adial Pharmaceuticals, Inc. (Nasdaq: ADIL) (“Adial” or the “Company”) today announced that it has acquired Azora Therapeutics, Inc. (“Azora”), a biopharmaceutical company developing treatments for serious inflammatory diseases. The acquisition brings Azora’s lead asset AT177, a proprietary colon‑targeted aryl hydrocarbon receptor (AhR) agonist designed to enable localized activation with limited systemic exposure, into Adial’s pipeline.

06/11/2026

Luna Labs Launches 3 Waves Venture Spinout to Commercialize Advanced Vestibular Stimulation Technology

Luna Labs today announced the launch of 3 Waves, Inc. (“3Waves”), a dual-use spinout company that was established to commercialize advanced virtual and mixed reality technologies for defense, commercial simulation, and medical applications. As part of the spinout, 3Waves and Mayo Clinic executed an exclusive license to support the development of next-generation vestibular stimulation systems

06/02/2026

TearSolutions Receives FDA Orphan Drug and Fast Track Designations for Lacripep® in Neurotrophic Keratitis and Initiates Phase 2 Clinical Trial with First Patients Dosed

TearSolutions, Inc. (“TearSolutions”), a clinical-stage biotechnology company developing novel ophthalmic therapeutics, today announced receiving Food and Drug Administration (FDA) Orphan Drug (ODD) and Fast Track Designations for Lacripep in Neurotrophic Keratitis (NK) and initiating a Phase 2 clinical trial with first patients dosed. The FDA’s ODD provides incentives, including tax credits for clinical testing and